Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Nov 1;5(6):1521-8.
doi: 10.1177/193229681100500629.

Pancreatic polypeptide administration enhances insulin sensitivity and reduces the insulin requirement of patients on insulin pump therapy

Atoosa Rabiee  1 , Panagis Galiatsatos, Rocio Salas-Carrillo, Michael J Thompson, Dana K Andersen, Dariush Elahi
Affiliations
Randomized Controlled Trial

Pancreatic polypeptide administration enhances insulin sensitivity and reduces the insulin requirement of patients on insulin pump therapy

Atoosa Rabiee et al. J Diabetes Sci Technol. .

Abstract

Introduction: The effects of pancreatic polypeptide (PP) infusion were examined in patients on insulin pump therapy to determine whether PP administration can reduce insulin requirements in patients with type 1 diabetes mellitus (T1DM) or type 3c diabetes mellitus (T3cDM; pancreatogenic).

Methods: Ten subjects with long-standing T1DM (n = 7) or T3cDM (n = 3) on insulin pump treatment received a 72 h subcutaneous infusion of 2 pmol/kg/min bovine PP or saline by portable infusion pump in a single-blinded, randomized, crossover design.

Results: Pancreatic polypeptide infusion raised plasma PP levels to 450-700 pmol/liter. Daily insulin infusion requirements (I) fell from 48 ± 6.9 to 40 ± 7.5 U on day 2 (p < .05) and from 46 ± 7.7 to 37 ± 6.6 U on day 3 (p < .05) of PP infusion compared with saline. Corrected for average blood glucose concentration (G), I/G fell in 10/10 subjects during the second 24 h period and in 7/10 subjects during the third 24 h period; sensitivity to insulin, calculated as 1/(I/G), increased 45% ± 12% on day 2 (p < .01) and 34% ± 14% on day 3 (p < .05) of PP infusion. Pancreatic polypeptide responses to a test meal were compared with the change in insulin infusion requirements in 5 subjects; the reduction in insulin requirements seen during PP infusion correlated with the degree of baseline PP deficiency (p < .002).

Conclusions: A concurrent subcutaneous infusion of PP enhances insulin sensitivity and reduces insulin requirements in patients with long-standing T1DM and T3cDM on insulin pump therapy. The benefit of PP infusion correlated with the degree of PP deficiency.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Plasma PP levels during a STM administered at time 0 during the last 3 h of the 72 h infusion of PP or saline in five subjects (mean ± SE).
Figure 2
Figure 2
Change in total daily insulin infusion requirement (I) during PP infusion compared with saline infusion during day 2 and day 3 of 72 h infusion periods. The reduction in daily insulin requirements averaged 8.4 ± 3.44 U on day 2 (p < .05) and 9.0 ± 3.49 U on day 3 (p < .05).
Figure 3
Figure 3
Total daily insulin infusion requirement (I)/average daily blood glucose level (G) ratios during 72 h saline infusion or 72 h PP infusion in 10 subjects (7 with T1DM and 3 with T3cDM) on insulin pump treatment during day 2 and day 3 of infusions. The I/G ratios for PP infusion versus saline infusion were reduced by 28% ± 4.8% on day 2 (p < .001) and by 17% ± 10% on day 3 (p < .05).
Figure 4
Figure 4
Correlation of percentage reduction in daily insulin infusion requirement (I)/average daily blood glucose level (G) ratio observed during PP infusion versus saline infusion and AUC of plasma PP response to the baseline STM in five diabetes subjects on insulin pump therapy (p < .002).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Taylor IL. Pancreatic polypeptide family: pancreatic polypeptide, neuropeptide Y and peptide YY. 2nd ed. Bethesda: American Physiological Society; 1989.
    1. Kono T, Wang XP, Fisher WE, Andersen DK, Brunicardi FC. Pancreatic polypeptide. In: Martini L, editor. Encyclopedia of endocrine diseases. Vol. 3. San Diego: Elsevier; 2004. pp. 488–496.
    1. Schwartz TW, Rehfeld JF, Stadil F, Larson LI, Chance RE, Moon N. Pancreatic-polypeptide response to food in duodenal-ulcer patients before and after vagotomy. Lancet. 1976;1(7969):1102–1105. - PubMed
    1. Orci L, Malaisse-Lagae F, Baetens D, Perrelet A. Pancreatic-poly-peptide-rich regions in human pancreas. Lancet. 1978;2(8101):1200–1201. - PubMed
    1. Hazelwood RL. The pancreatic polypeptide (PP-fold) family: gastro-intestinal, vascular, and feeding behavioral implications. Proc Soc Exp Biol Med. 1993;202(1):44–63. - PubMed

Publication types